Combined androgen blockade with bicalutamide for advanced prostate cancer: Long-term follow-up of a phase 3, double-blind, randomized study for survival Department of Urology, Institute of Clinical Medicine, University of Tsukuba, Ibaraki, Japan has released some very significant survival data about a previously reported, double-blind, randomized, multicenter phase 3 trial. This trial compared combined androgen blockade [...]
There was just a release of some of the data from the on-going review sipuleucel-T, or Provenge, in men with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but who have not yet developed metastatic prostate cancer. The data wes presented by Oregon Health & Realm University Cancer [...]
There is some good news on the horizon, or at least we are setting up for the possibility of some future good news. Coming off of the recent news about the very successful phase II trial of CB7630 (abiraterone acetate), Cougar Biotechnology, Inc. has reached agreement with the FDA under a special protocol assessment (SPA) [...]
Researchers at Purdue have developed what they have described as prostate cancer “homing device.” They believe that this treatment modality can improve detection, and allow for the first targeted treatment of prostate cancer. The researchers have synthesized a molecule that finds and penetrates only prostate cancer cells. They have also created imaging agents and therapeutic [...]
Selenium is one of those supplements that were are told is good for us and then we are told it is bad for us. Every six months to a year the story and the recommendations seem to change. According to a study by researchers at Dana-Farber Cancer Institute the University of California, San Francisco higher [...]
On June 27, 2009, Gina Kolata’s article in the New York Times on the too safe nature of funding from the National Institute of Health (NIH) struck a chord for many of us. She opens the article with the following, “Among the recent research grants awarded by the National Cancer Institute is one for a [...]
Men with advanced prostate cancer who develop an adrenal tumor will usually undergo laparoscopic adrenalectomy (removal of the adrenal gland) as a treatment method. Just like with prostate surgery. in some situations surgery might not be the best alternative for an individual man. An individual case was recently completed at the Department of Renal and [...]
A presentation at the ASCO conference in Florida reconfirmed the fact that increased levels of C-reactive protein (CRP) is associated with adverse outcomes (earlier death) in men with castration-resistant prostate cancer (CRPC) treated with docetaxel (taxotere). The study analyzed the baseline serum samples from 119 castrate resistant (CRPC) men enrolled in 6 phase I or [...]
There is a new study that shows that an alpha-particle emitting radiopeptide—radioactive material bound to a synthetic peptide, a component of protein—is effective for treating prostate cancer in mice, according to researchers. The conclusions of this study could eventually (still years away if it also works in men) result in a significant breakthrough in advanced [...]
On Thursday the Senate Appropriations subcommittee on Labor, Health and Human Services, and Education held its FY 2010 NIH budget hearing. There were two particular items of note for the cancer community. When discussing the NIH funding which was received through the economic stimulus package, Senator Harkin questioned if the current two years the NIH [...]
